CHMP issues positive opinion to expand INVOKANA & VOKANAMET labels to include positive data on cardiovascular(CV) & renal outcomes
Shots:
- Mundipharma has gained exclusive distribution rights from Janssen for Europe and Switzerland excluding Spain
- The drug is recommended for Type 2 Diabetes Mellitus (T2DB) patients with adverse CV disease or atleast 2 CV risk factors
- The Type 2 variation application is based on CANVAS programme included 10-000 patients treated since 2009- showed reduction in CV death- myocardial infarction and non-fatal stroke VS placebo in adults with T2DB
/ article | Ref: Mundipharma | Image: Mundipharma
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
